Asthma Management with ICS and SABA

Mechanism of Action and Effectiveness

ICS taken in combination with SABAs can decrease the frequency and severity of exercise-induced bronchoconstriction and other acute asthma symptoms, according to the American Academy of Allergy, Asthma, and Immunology 1, 2
While LAMAs can be effective bronchodilators, they provide inconsistent results in attenuating acute symptoms and are not primarily indicated for short-term relief, as stated by the American Academy of Allergy, Asthma, and Immunology 1, 2

The National Asthma Education and Prevention Program recommends SABA as the primary quick-relief medication for all patients, with the intensity of treatment depending on symptom severity 3
For short-term prophylaxis against exercise-induced bronchoconstriction, a single dose of SABA is recommended, which provides protection for 2-4 hours, according to the American College of Allergy, Asthma, and Immunology 1
The National Asthma Education and Prevention Program guidelines support the use of as-needed ICS with SABA for symptom relief in patients with mild persistent asthma, with a strength of evidence rated as high 4, 5

LAMAs are primarily recommended as controller medications rather than for quick symptom relief, as stated by the National Asthma Education and Prevention Program 4, 6
The Expert Panel conditionally recommends against adding LAMA to ICS compared to adding LABA to ICS in uncontrolled persistent asthma, suggesting LAMAs are not the preferred bronchodilator option, with a moderate strength of evidence 6
Anticholinergic agents, including LAMAs, provide inconsistent results in attenuating exercise-induced bronchoconstriction, making them less reliable for short-term relief, according to the American Academy of Allergy, Asthma, and Immunology 2

Increasing use of SABA for symptom relief generally indicates inadequate asthma control and may require a step up in treatment, as recommended by the National Asthma Education and Prevention Program 3
Daily use of beta-agonists alone or in combination with ICS can lead to tolerance, manifested as reduced duration and magnitude of protection, with a high strength of evidence 1, 2
For patients with persistent asthma requiring regular controller therapy, ICS-formoterol combinations may be preferred for both maintenance and reliever therapy in moderate to severe persistent asthma, according to the National Asthma Education and Prevention Program 4, 5

In exercise-induced bronchoconstriction, SABAs are most effective for short-term protection and accelerating recovery, as stated by the American College of Sports Medicine 7
For patients with frequent symptoms requiring regular controller therapy, adding a LAMA to ICS-LABA combination may be considered, but this is for long-term control rather than short-term relief, with a low strength of evidence 6